Wild-type (senile) ATTR amyloidosis surgery

Wild-type (senile) ATTR amyloidosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Wild-type (senile) ATTR amyloidosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Wild-type (senile) ATTR amyloidosis surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Wild-type (senile) ATTR amyloidosis surgery All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Wild-type (senile) ATTR amyloidosis surgery
CDC on Wild-type (senile) ATTR amyloidosis surgery
Wild-type (senile) ATTR amyloidosis surgery in the news
Blogs on Wild-type (senile) ATTR amyloidosis surgery
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Wild-type (senile) ATTR amyloidosis surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

Liver transplantation is the mainstay of treatment for wild-type ATTR amyloidosis.

Surgery

Liver transplantation is the mainstay of treatment for wild-type ATTR amyloidosis.

• Transplantation replaces the main source of variant TTR with a source of normal-sequence TTR.
• This leads to gradual fibril reabsorption and disease stabilization, especially of neurologic complications.